ERCC1基因多态性与乳腺癌蒽环类药物新辅助化疗疗效的相关性研究

目的研究ERCC1基因多态性与乳腺癌蒽环类药物新辅助化疗疗效的相关性。方法随机选取2012年8月至2015年8月收治的46例乳腺癌患者，依据术前治疗情况将患者分为两组，即接受蒽环类药物新辅助化疗组（化疗组，n=18）和未接受任何治疗组（未化疗组，n=28）。不对化疗组患者进行临床病理特征分析，对未化疗组患者进行临床病理特征分析，对其进行RT-PCR检测，然后对未化疗组患者ERCC1基因的表达水平及两组患者的ERCC1表达水平进行统计分析。结果未化疗组不同年龄、肿块大小、病理类型、组织学分级、腋淋巴结、PR、ER、HER．2患者ERCC1基因的表达水平之间的差异均不显著（P〉0．05）；化疗组患者的ERCC1表达水平显著高于未化疗组（P〈0．05）。结论ERCC1基因表达水平会在乳腺癌蒽环类药物新辅助化疗的作用下提升。

Objective To study the relationship between ERCC1 gene polymorphisms and efficacy ofneoadjuvant anthraeycline chemotherapy of breast cancer. Methods 46 cases of patients with breast cancer in our hospital during August 2012 to August 2015 were randomly selected, these patients were divided into two groups according to preoperative treatment, namely acceptance anthracycline neoadjuvant chemotherapy group （ chemotherapy group, n=18 ） and did not receive any treatment group （ no chemotherapy group, n=54 ） . The no chemotherapy group were not given clinical and pathological features analysis, while the chemotherapy group were given clinical and pathological features analysis, RT-PCR were detected, and then the ERCC1 gene expression levels of the no chemotherapy group and the ERCC1 expression levels of the two groups were statistically analyzed. Results The differences of ERCC 1 gene expression levels of the no chemotherapy group between different ages, tumor sizes, histological types, histologicalgrades, axillary lymph nodes, PR, ER, HER-2 were not significant （ P〉0.05 ） ; the ERCC1 expression level of the chemotherapy group were significantly higher than the no chemotherapy group （ P〈0.05 ） . Conclusions ERCC1 gene expression level can improve under the effect of neoadjuvant anthracycline chemotherapy of breast cancer.